Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 6,990 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Completed Phase 2 Interventional Results available

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

NCT01471106
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 16, 2026, 3:55 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

NCT05677048
View directory record Official record
Conditions
Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions
Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

NCT01254526
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0980, bevacizumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 3:55 AM EDT
Suspended No phase listed Observational

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

NCT02313116
View directory record Official record
Conditions
Breast Cancer
Interventions
Interferometric Synthetic Aperture Microscopy
Device
Lead sponsor
Diagnostic Photonics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Herceptin and GM-CSF for Metastatic Breast Cancer

NCT00429104
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, GM-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

NCT00083148
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Patient-Assisted Compression - Impact on Image Quality and Workflow

NCT03196635
View directory record Official record
Conditions
Breast Cancer
Interventions
Patient-Assisted (PA) Breast Compression, Technologist-Controlled (TC) Breast Compression
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
40 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 16, 2026, 3:55 AM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

NCT02179515
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others), Ovarian Cancer
Interventions
MVA-brachyury- TRICOM
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908
View directory record Official record
Conditions
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 16, 2026, 3:55 AM EDT
Active, not recruiting No phase listed Observational

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462
View directory record Official record
Conditions
Ophthalmic Safety in Patients With Breast Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
La Jolla, California • Palo Alto, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 16, 2026, 3:55 AM EDT
Withdrawn Not applicable Interventional

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

NCT01936961
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer
Interventions
CTLA-4 Antibody, Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

NCT00036270
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane (Aromasin), tamoxifen + exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older · Female only
Enrollment
9,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
179
States / cities
Bessemer, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 16, 2026, 3:55 AM EDT
Terminated Not applicable Interventional Results available

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

NCT00503841
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 16, 2026, 3:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

NCT02658084
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Vinorelbine, Trastuzumab Emtansine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 16, 2026, 3:55 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

NCT01545648
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Hope Rugo, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 16, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Breast Cancer AI Imaging Study

NCT06604078
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Screening
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer

NCT03375827
View directory record Official record
Conditions
Breast Cancer
Interventions
IGCDG
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 16, 2026, 3:55 AM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib in Patients With Breast Cancer

NCT01562873
View directory record Official record
Conditions
Breast Cancer
Interventions
Ruxolitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 16, 2026, 3:55 AM EDT
Completed No phase listed Observational

Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

NCT00941759
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

NCT05113927
View directory record Official record
Conditions
Breast Cancer
Interventions
Selene
Device
Lead sponsor
Perimeter Medical Imaging
Industry
Eligibility
18 Years and older · Female only
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Tampa, Florida • Meadowbrook, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Not applicable Interventional

A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors

NCT04594473
View directory record Official record
Conditions
Breast Cancer
Interventions
Comprehensive Oncology Rehabilitation and Exercise (CORE) Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 16, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 16, 2026, 3:55 AM EDT